Live data · NADAC + Part D CY24 · reviewed daily

Xenon Xe 129 Hyperpolarized (XENOVIEW)

Hyperpolarized Contrast Agent class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2022-12-23
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Xenon Xe 129 Hyperpolarized used for?

Xenon Xe 129 Hyperpolarized is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Xenon Xe 129 Hyperpolarized?

No. Xenon Xe 129 Hyperpolarized is brand-only with no generic equivalents currently in market.

How much does my plan pay for Xenon Xe 129 Hyperpolarized?

NADAC pricing data not currently available for this drug.

Is Xenon Xe 129 Hyperpolarized on the FDA shortage list?

No. Xenon Xe 129 Hyperpolarized is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.